UK: Deal Or No Deal – Government Opens The (First) Box

Last Updated: 10 October 2018
Article by Edward Turtle and Sarah-Jane Dobson

In the first in a series, we examine the Government's plans for products in the event of a "No Deal" Brexit.

The UK Government has been publishing technical notices, setting out its plans in the event that the UK and the EU fail to reach agreement before March 2019. Following publication of the last batch at the end of September, we take a look at what has been announced so far, from the standpoint of product manufacturers who need to make informed contingency preparations. This is the first in the series; stay tuned for further instalments.

It is evident from the first batch of technical notices that a "no deal" scenario will not be plain sailing for businesses. Additional hurdles for food producers, changes to packaging and changes to processes for sale of medicines all suggest that, despite the Government's commitment to minimise disruption, there could be choppy waters ahead. Businesses will sometimes be required to take action immediately post-Brexit, whilst other changes will be able to be made more incrementally during a transition period.

Medicines and Medical Devices

As human health and safety are at the core of the medicines and medical devices sector, the Government has made clear its concern that regulation of these sectors is seamless post-Brexit.

Yet, even here it seems some change is inevitable. The biggest and most immediate changes are increased administrative burdens for manufacturers wishing to trade in the UK post-Brexit, with requirements to engage in a separate authorisiation process and for a mandatory regulatory presence (responsible person) in the UK. Products currently in the UK market, based on EU-approval, will remain unaffected, at least for the time being.

Areas which remain unchanged

The standard of safety required would be unaffected by a no deal scenario, either because UK legislation will continue to apply (organs, tissues and cells and blood and blood products), or because the Government suggests it will adopt EU safety standards, at least temporarily, post-Brexit (medicines, medical devices and clinical trials).

EU-certified products, including medical devices, blood and blood products and organs, tissues and cells would continue to be accepted, at least in the short term, in the UK. Similarly, EU-based batch testing could continue to be used for products manufactured in the EU and sold in the UK (with UK-based batch testing continuing to be required where products were manufactured in the UK).

Areas of change

UK-based notified bodies will no longer be able to assess conformity for compliance with EU requirements. Interestingly, there is no comment regarding the recognition of EU-based notified bodies by the UK.

Applications in respect of medicines, medical devices and clinical trials will now be submitted to MHRA in respect of UK-marketed products; necessitating multiple applications for products marketed in both the UK and EU market. MHRA will accept EU application forms, and adopt the same procedure for submission in most respects, but partially processed applications at the time of exit will need to be re-submitted separately to the UK, which will no longer be bound by decisions of the EU bodies.

QP, QPP and contact persons under these regimes will need to be UK-based, for QPP at the time of exit (unless the company has no UK presence, in which case they have until 2020) and change forms to indicate any changes will need to be submitted to the MHRA.

Whilst importation of EU blood, blood products, organs, tissues and cells will be secured unilaterally by the UK at the time of exit (with some additional administrative burden on importers), arrangements for exportation will not be, and those intending to export will be required to comply with the EU requirements.

The legal regimes attached to medicines, medical devices and clinical trials are the most affected by the Government's no-deal Brexit plans. The recent EU-level legislative changes in respect of medical devices and clinical trials, which will not be implemented in time for Brexit, necessitate the UK's, at least temporary, adoption of EU law to ensure continuity of regulation of these safety-critical areas (with amendments to reflect the change of the relevant authority to the UK's MHRA).

The technical notices make it clear that deviation from EU law will be permissible in respect of all of these regimes from the time of exit.

Future technical notes will be produced in respect of biological medicines, IT systems requirements and manufacturing and import licensing. We will provide updates when these are published. In addition, relevant EU bodies will be producing guidance on how they will handle UK-certified or manufactured products. We will provide updates in this regard as they become available also.

Product Labelling

The Government has published information that will affect businesses in the food, GMO and tobacco sectors. For other industries, contingency plans remain unclear so far.

Food producers should look carefully at plans for organic food products. European Organic Food Regulations (834/2007, 889/2008 and 1235/2008) would be transposed onto the UK statute book substantively intact and certification and traceability provisions would remain. However, EU organic packaging logos would have to change, with a grace period to use up existing stock. A new UK traceability system would replace EU TRACES NT. UK businesses would only be able to export to the EU if certified by a control body recognised by the European Commission. The Government is attempting to agree equivalency provisions in the interim.

Current EU requirements for GMOs would be maintained substantially intact, with the UK still making decisions on trials, but regulatory control of marketing would shift into its control. Businesses would only be able to import GMOs to the UK with UK approval, and export to the EU with EU approval.

Tobacco manufacturers should consider how they would prepare for new picture warnings and deal with existing stock if the UK exits the EU without agreement (the European Commission owns the copyright to the current library of graphic health warnings). Otherwise, it is business as usual with the UK signaling it would retain current legislation implementing the EU provisions.


The first batch of no deal plans are light on detail. With current uncertainties likely to persist for at least another few months, companies will have little time to adjust if the UK and the EU fail to reach agreement before March 2019.

That said, what has been published already highlights key points for product manufacturers.

  • The need for contingency plans. The UK Government claims that roughly 80% of the EU Withdrawal Agreement is now agreed and is at pains to point out that it considers the no deal scenario unlikely. The Secretary of State set out his justification for contingency planning: "Let me be clear about this. This is not what we want. And it's not what we expect. But, we must be ready. We have a duty as a responsible government to plan for every eventuality."

    Manufacturers must also be ready; they cannot afford to bank on a deal and should be preparing thorough business continuity plans now.
  • Targeting areas of change. The Government is clearly prioritising consistency to ensure as smooth a transition as possible. Businesses should be reviewing the technical notices and targeting areas of change in their contingency planning.
  • Watching the EU response. If the Government does not reach agreement with the EU in important areas, it has signaled that it is willing to go it alone and adopt unilateral harmonising measures – such as those in respect of batch testing of medicines. This appears to be premised on the assumption that the EU will follow suit, but there are certainly no guarantees on that front. It is important that businesses monitor EU as well as UK preparations to be best-placed to react to a no deal scenario. The European Commission's recent preparations guidance stresses that "although the withdrawal of the United Kingdom may appear to be playing out at a high and rather abstract level between the United Kingdom and the European Union, its consequences will be very real for citizens, professionals and business operators."

The full list of technical notices published so far is available here. We will continue to blog on No Deal plans as they are published.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions